+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Urologic An issue of Salvage therapies for Non-Muscle Invasive Bladder Cancer. The Clinics: Surgery Volume 47-1

  • Book

  • December 2019
  • Elsevier Health Science
  • ID: 4850310

Together with Consulting Editor Dr. Samir Taneja, Dr. Badrinath Konety has put together a comprehensive issue that addresses Salvage therapies for Non-Muscle Invasive Bladder Cancer. Expert authors have contributed clinical review articles on the following topics:� BCG salvage therapy: Definition and context; Who will respond to BCG? Predictors and nomograms; Identification of candidates for salvage therapy: Definition of BCG "Failure�; Predictors of response to Intravesical therapy; Precision medicine for NMIBC; Salvage therapy using BCG derivatives or single agent chemotherapy; Intravesical heated Mitomycin: Biology and clinical utility; Mitomycin derivatives in the salvage setting; Combination intravesical therapy; Intravesical gene therapy; Immunoncology as salvage therapy; Role of IDO inhibitors in salvage therapy; and Novel agents for intravesical therapy.� Readers will come away with the clinical information they need to improve outcomes in patients with bladder cancer.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Authors

Badrinath Konety